- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07460323
Badanie uszczelnień TRE u pacjentów we wczesnym okresie pooperacyjnym
Badanie uszczelnień TRE u wczesnych pacjentów pooperacyjnych
This study will evaluate two Ostomy Seals/Rings in a group of post-operative patients.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: John Whitaker; Chief Investigator
- Numer telefonu: 27148 024 7696 7148
- E-mail: John.Whitaker@uhcw.nhs.uk
Lokalizacje studiów
-
-
County Durham
-
Stockton-on-Tees, County Durham, Zjednoczone Królestwo, TS19 8PE
- Rekrutacyjny
- North Tees University Hospital
-
Kontakt:
- Abdalla Mustafa
- Numer telefonu: 7940211807
- E-mail: abdallamustafa1@nhs.net
-
-
East Sussex
-
Saint Leonards-on-Sea, East Sussex, Zjednoczone Królestwo, TN37 7RD
- Rekrutacyjny
- East Sussex Healthcare NHS Trust: Conquest and Eastbourne Hospitals
-
Kontakt:
- Janet Sinclair
- Numer telefonu: 7741408250
- E-mail: janet.sinclair4@nhs.net
-
-
Kent
-
Ashford, Kent, Zjednoczone Królestwo, TN24 0LZ
- Rekrutacyjny
- William Harvey Hospital
-
Kontakt:
- Lalmaya Pun
- Numer telefonu: 1233616646
- E-mail: lalmaya.pun@nhs.net
-
Margate, Kent, Zjednoczone Królestwo, CT9 4AN
- Rekrutacyjny
- Queen Elizabeth The Queen Mother Hospital
-
Kontakt:
- Susan Biles
- Numer telefonu: 1233616646
- E-mail: susan.biles@nhs.net
-
-
North Yorkshire
-
Middlesbrough, North Yorkshire, Zjednoczone Królestwo, TS4 3BW
- Rekrutacyjny
- South Tees University Hospital
-
Kontakt:
- Anil Reddy
- Numer telefonu: 01642 850850
- E-mail: Anil.reddy@nhs.net
-
-
Surrey
-
Redhill, Surrey, Zjednoczone Królestwo, RH1 5RH
- Rekrutacyjny
- East Surrey Hospital
-
Kontakt:
- Mathew Varghese
- Numer telefonu: 01737 231728
- E-mail: mathew.varghese8@nhs.net
-
-
West Midlands
-
Coventry, West Midlands, Zjednoczone Królestwo, CV2 2DX
- Rekrutacyjny
- University Hospital Coventry
-
Kontakt:
- Michelle Hicken
- Numer telefonu: 27148 024 7696 7148
- E-mail: michelle.hicken@uhcw.nhs.uk
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- At least 18 years of age
- Has their ostomy surgery and post-operative care in the United Kingdom (UK)
- Has a colostomy, ileostomy, or urostomy and no reversal planned during the study evaluation period
- Able to have first study product applied at first pouch change after surgery (or up to 4 days post-op)
- Is appropriate to use a barrier seal per the Investigator
- Able to provide an informed consent for study participation
- Willing to follow protocol procedures, including participating in study visits, as demonstrated by signing the informed consent
Exclusion Criteria:
- Is over 85 years of age
- Has received chemotherapy or radiation in the past 30 days or reports beginning chemotherapy or radiation during the study.
- A score of 1, 2, or 3 for any of the three OCSI Tool PSC-related domains (i.e., peristomal irritant dermatitis, peristomal bleeding, and hyperplasia) at time of enrollment
- Has a fistula in the peristomal area at time of enrollment
- Has an open draining wound (not including mucocutaneous separation) in the peristomal area at time of enrollment
- Has a suspected infection in the peristomal area at time of enrollment
- Is pregnant or lactating at time of enrollment (as determined by interview only)
- Is unable to speak, read, and understand English.
- Is currently participating in another clinical study using ostomy products
- Is currently an employee of Hollister Incorporated or any ostomy manufacturer
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: Uszczelka stomijna
|
An absorptive ostomy seal |
|
Aktywny komparator: Pierścień stomijny
|
The Ostomy Ring contains Aloe |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
The Risk of Peristomal Skin Complications (PSCs) as measured using the three PSC-related questions on the Ostomy Complication Severity Index (OCSI)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
The three PSC-related questions on the Ostomy Complication Severity Index (OCSI) are related to peristomal irritant dermatitis, peristomal bleeding, and hyperplasia. Each of these three items is rated on a scale of 0-3, with 0 indicating absence of the condition, and 3 indicating the condition is severe. |
From enrollment to the end of treatment at 9 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Total Ostomy Complication Severity Index (OCSI) score and six stomal complication (non-PSC) domains of the OCSI and associated severity
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Each of the OCSI items are scored on a scale of 0-3, with 0 indicating absence of the condition and 3 indicating the condition is severe. |
From enrollment to the end of treatment at 9 weeks
|
|
Mediation of peristomal skin complications (PSCs) by leakage absorption measured using the leakage item on the Ostomy Complication Severity Index (OCSI)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
The leakage item on the OCSI has a scale of 0 (no leakage) to 3 (leakage approximately 1-2 times per day) |
From enrollment to the end of treatment at 9 weeks
|
|
Visible moisture/effluent on peristomal skin under the study seal area (OCSI Supplementary Question)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Assessed only if leakage is reported in the OCSI tool (conditional). Responses: Great amount / Slight amount / None (ordinal categorical). |
From enrollment to the end of treatment at 9 weeks
|
|
Seal absorption of moisture/effluent under the study seal area (OCSI Supplementary Question)
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Participant response to whether the study seal absorbed moisture/effluent from around the stoma/peristomal skin under the seal. Responses: Yes / Somewhat / No, not at all (ordinal categorical). |
From enrollment to end of treatment at 9 weeks
|
|
Presence of peristomal skin conditions (OCSI Supplementary Question)
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Checklist of skin conditions present: burning, itching, maceration, fungal rash, folliculitis, granuloma, mechanical trauma, product sensitivity/allergy, pyoderma gangrenosum, other, none. |
From enrollment to end of treatment at 9 weeks
|
|
Peristomal skin burning severity (OCSI Supplementary Question)
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Rated on a numeric scale from 0 (absent) to 10 (worst burning imaginable). Assessed only if burning is reported (conditional logic from Q25). Higher scores indicate worse burning. |
From enrollment to end of treatment at 9 weeks
|
|
Peristomal skin itching severity (OCSI Supplementary Question)
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Rated on a numeric scale from 0 (absent) to 10 (worst itching imaginable). Assessed only if itching is reported (conditional logic from Q25). Higher scores indicate worse itching. |
From enrollment to end of treatment at 9 weeks
|
|
Time to resolution of peristomal skin complications (PSCs), assessed by the Ostomy Complication Severity Instrument (OCSI) at visits and adverse event (AE) reports between visits
Ramy czasowe: From first PSC onset to resolution through end of treatment at 9 weeks
|
Unit of Measure: days |
From first PSC onset to resolution through end of treatment at 9 weeks
|
|
Time to recurrence of peristomal skin complications (PSCs) after resolution, assessed by the OCSI at visits and AE reports between visits
Ramy czasowe: From PSC resolution to first recurrence through end of treatment at 9 weeks
|
Unit of Measure: days |
From PSC resolution to first recurrence through end of treatment at 9 weeks
|
|
Proportion of participants with PSC occurrence, PSC resolution, and PSC recurrence, assessed by the OCSI at visits and AE reports between visits
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Unit of Measure: percent (%) |
From enrollment to end of treatment at 9 weeks
|
|
Patient satisfaction with the study Seal/Ring assessed using the Study-Specific Patient Satisfaction Questionnaire (Likert scale)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied) |
From enrollment to the end of treatment at 9 weeks
|
|
Clinician Satisfaction with the study Seal/Ring assessed using the Study-Specific Clinician Satisfaction Questionnaire (Likert scale)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Rated on a 5-point Likert scale from 1 (Very Satisfied) to 5 (Very dissatisfied) |
From enrollment to the end of treatment at 9 weeks
|
|
Ability to correctly use the seal/ring with available instructional resources, assessed by the Study-Specific Instructional Resources Question
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Single study-specific question assessing whether instructional resources (e.g., IFU, online guides) enabled correct use of the seal/ring; responses: Yes / No / Did not use instructional resources. Results will be reported as the proportion of participants in each response category. |
From enrollment to the end of treatment at 9 weeks
|
|
Seal swelling/expansion incidence, assessed by Study-Specific Swell/Expand Question
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Participant response comparing seal size at application versus at barrier change. Responses: No, seal did not swell/expand / Yes, seal swelled/expanded. |
From enrollment to the end of treatment at 9 weeks
|
|
Effectiveness of seal swelling/expansion for secure fit against leakage, assessed by Study-Specific Swell/Expand Question
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Participant response regarding whether swelling/expansion provided a better, more secure fit against leakage. Responses: No, not at all / Yes, somewhat / Yes, definitely (ordinal categorical). |
From enrollment to end of treatment at 9 weeks
|
|
Perceived moisture-wicking effect, assessed by the Study-Specific Moisture-Wicking Question (3-point scale)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Single study-specific question assessing perceived moisture-wicking away from peristomal skin. Responses: No, not at all / Yes, somewhat / Yes, definitely. |
From enrollment to the end of treatment at 9 weeks
|
|
Clinician agreement with the study Seal/Ring performance assessed using the Study-Specific Clinician Agreement Questionnaire (Likert scale)
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Rated on a 5-point Likert scale from 1 (Strongly agree) to 5 (Strongly disagree) |
From enrollment to the end of treatment at 9 weeks
|
|
Quantity of seals/rings, barriers, and accessories used, assessed by Study-Specific Resource Utilization Log
Ramy czasowe: From enrollment to the end of treatment at 9 weeks
|
Unit of measure: mean/median number used per participant (counts) |
From enrollment to the end of treatment at 9 weeks
|
|
Wear/use time (longevity) of seals/rings and barriers, assessed by Study-Specific Resource Utilization Log
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Unit of measure: hours or days of wear time per application (time) |
From enrollment to end of treatment at 9 weeks
|
|
Peristomal skin-related unplanned healthcare visits, assessed by Study-Specific Healthcare Utilization Question
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Unit of measure: number of visits per participant; optionally proportion with ≥1 visit (counts/%) |
From enrollment to end of treatment at 9 weeks
|
|
Total ostomy seal/ring costs, derived from quantities recorded in the Resource and Healthcare Utilization Logs
Ramy czasowe: From enrollment to end of treatment at 9 weeks
|
Unit of measure: currency (e.g., dollars) |
From enrollment to end of treatment at 9 weeks
|
Współpracownicy i badacze
Sponsor
Śledczy
- Krzesło do nauki: John Whitaker, University Hospital Coventry
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Inne numery identyfikacyjne badania
- 6042-OST
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .